Scientists probe immune Cells' role in scleroderma blood vessel injury
NCT ID NCT02636127
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at how certain immune cells (T cells and NK cells) might damage blood vessels in people with systemic sclerosis, a rare autoimmune disease. Researchers analyzed blood samples from 30 participants to measure a protein called Fractalkine and study cell interactions. The goal was to better understand the disease process, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward new treatment targets for systemic sclerosis by clarifying how immune cells injure blood vessels.
- What could go wrong
- This is a small, observational study with only 30 participants, so findings may not apply to all patients. It does not test a treatment, so direct benefits are unlikely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assistance Publique Hopitaux de Marseille
Marseille, 13354, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Are women with autoimmune diseases getting the gynecological care they need?
- New shot aims to tame rare autoimmune disease
- Cancer drug shows promise for rare skin disease
- New drug hope for scleroderma patients with lung complications
- New hope for scleroderma: arthritis drug tofacitinib tested against skin thickening
- Immune cell therapy takes on tough scleroderma